Method Article

Transfection, Selection, and Colony-picking of Human Induced Pluripotent Stem Cells TALEN-targeted with a GFP Gene into the AAVS1 Safe Harbor

DOI:

10.3791/52504

February 1st, 2015

 ,  ,  , 

Corresponding Authors: Jizhong Zou <jizhong.zou@nih.gov>

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

TALEN-mediated gene editing at the safe harbor AAVS1 locus enables high-efficiency transgene addition in human iPSCs. This protocol describes the procedures for preparing iPSCs for TALEN and donor vector delivery, transfecting iPSCs, and selecting and isolating iPSC clones to achieve targeted integration of a GFP gene to generate reporter lines.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Targeted transgene addition can provide persistent gene expression while circumventing the gene silencing and insertional mutagenesis caused by viral vector mediated random integration. This protocol describes a universal and efficient transgene targeted addition platform in human iPSCs based on utilization of validated open-source TALENs and a gene-trap-like donor to deliver transgenes into a safe harbor locus. Importantly, effective gene editing is rate-limited by the delivery efficiency of gene editing vectors. Therefore, this protocol first focuses on preparation of iPSCs for transfection to achieve high nuclear delivery efficiency. When iPSCs are dissociated into single cells using a gentle-cell dissociation reagent and transfected using an optimized program, >50% cells can be induced to take up the large gene editing vectors. Because the AAVS1 locus is located in the intron of an active gene (PPP1R12C), a splicing acceptor (SA)-linked puromycin resistant gene (PAC) was used to select targeted iPSCs while excluding random integration-only and untransfected cells. This strategy greatly increases the chance of obtaining targeted clones, and can be used in other active gene targeting experiments as well. Two weeks after puromycin selection at the dose adjusted for the specific iPSC line, clones are ready to be picked by manual dissection of large, isolated colonies into smaller pieces that are transferred to fresh medium in a smaller well for further expansion and genetic and functional screening. One can follow this protocol to readily obtain multiple GFP reporter iPSC lines that are useful for in vivo and in vitro imaging and cell isolation.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The ability to reprogram human somatic cells into embryonic stem cell-like induced pluripotent stem cells (iPSCs) was first discovered by Takahashi et al. in 20071. Human dermal fibroblasts transduced with retroviruses expressing four transcription factors (The so-dubbed Yamanaka factors Oct3/4, Sox2, c-Myc, and Klf4) were shown to be highly similar to human embryonic stem cells (hESCs) based on morphology, proliferation, gene expression, and epigenetic status; crucially, iPSCs are also capable of differentiating into cells of all three germ layers1. The proliferative potential and differentiation capacity of iPSCs makes them very attrac....

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

1. Preparation of Basement Membrane Matrix and Coating of Plasticware

  1. Place the frozen basement membrane matrix stock from -20 °C onto ice and thaw overnight at 4 °C.
  2. After thawing, pipette 2 mg aliquots of basement membrane matrix into pre-chilled eppendorf tubes. Store these at -20 °C until needed.
  3. To prepare basement membrane matrix-coated plates, thaw one aliquot on ice until the last piece of ice in the eppendorf tube disappears (usually within ~2 hr).
  4. After thawing, add basement membrane matrix to 12 ml of cold (4 °C) DMEM/F12 to make basement membrane matrix coating solution.
  5. Add basem....

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

A visualization of the protocol is provided in Figure 2, with periods during which iPSCs are cultured in different medium highlighted by either green for E8 or blue for NutriStem. It is important to transfect only high-quality iPSCs; examine culture dishes throughout routine maintenance and verify that iPSC cultures contain mainly distinct colonies bearing a cobblestone-like morphology (Figure 3A); differentiated cells should not occupy more than 10% of the culture. Transfectability of i.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The most critical steps for the successful generation of AAVS1 safe-harbor targeted human iPSCs are: (1) efficiently delivering TALEN and donor plasmids into iPSCs by transfection; (2) optimizing dissociation of iPSCs into single cells before transfection and plating density after transfection; (3) optimizing dose and time of drug-selection based on the growth of iPSC line; (4) carefully dissecting and picking targeted colonies and transferring to new plate/well. Compared to similar methods used in Hockemeyer’s pap.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors declare that they have no competing financial interests.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This research was supported by the NIH Common Fund and Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix, *LDEV-Free, 10 mlCorning354230Store at -20 °C.
DMEM/F-12Life Technologies11320-033Store at 4 °C.
Costar 6 Well Clear TC-Treated Multiple Well PlatesCorning3506
Essential 8 MediumLife TechnologiesA1517001Store basal medium at 4 °C. Store supplement at -20 °C.
Y-27632 dihydrochlorideTocris1254Store at room temp. Once dissolved in H2O, store at -20 °C.
Sodium ChlorideSigmaS5886-500G
UltraPure 0.5 M EDTA, pH 8.0Life Technologies15575-020
DPBS, no calcium, no magnesiumLife Technologies14190-250
100 mm TC-Treated Culture DishCorning430167
DR4 MEF 2M IRR - AcademicGlobalStemGSC-6204GStore in liquid Nitrogen.
DMEM, high glucose, pyruvateLife Technologies11995-040Store at 4 °C.
Defined Fetal Bovine Serum, US OriginHyCloneSH30070.03Store at -20 °C. Thaw at 4 °C overnight and aliquot. Store aliquots at -20 °C until needed.
MEM Non-Essential Amino Acids Solution (100X)Life Technologies11140-050Store at 4 °C.
4D-Nucleofector Core unit LonzaAAF-1001Bpart of the electroporation system
4D-Nucleofector X unit LonzaAAF-1001Xpart of the electroporation system
P3 Primary Cell 4D-Nucleofector X Kit L (24 RCT)LonzaV4XP-3024Upon arrival, remove Primary Cell Solution and supplement and store at 4 °C.
StemPro Accutase Cell Dissociation ReagentLife TechnologiesA1110501Store at -20 °C. Thaw overnight at 4°C and warm an aliquot in a 37 °C water bath before use.
NutriStem XF/FF Culture MediumStemgent01-0005Store at -20 °C. Thaw overnight at 4 °C
AAVS1 TALENs (pZT-AAVS1-L1 and pZT-AAVS1-R1)Addgene52637 and 52638
[header]
AAVS1-CAG-EGFP Homologous Recombination donorAddgene22212
Puromycin DihydrochlorideLife TechnologiesA11138-03Store at -20 °C. Prepare working aliquots of 1 mg/ml in ddH2O.
Disposable Borosilicate Glass Pasteur PipetsFisher Scientific13-678-20A
Sorvall Legend XTR (Refrigerated), 120 V 60 HzThermo Scientific75-004-521
TX-750 4 × 750 ml Swinging Bucket RotorThermo Scientific75003607
Trypan Blue Solution, 0.4%Life Technologies15250-061

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131 (5), 861-872 (2007).
  2. Hentze, H., Graichen, R., Colman, A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotec....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Human iPSCsTALEN TargetingNucleofection TransfectionPuromycin SelectionGFP Reporter ExpressionFlow Cytometry AnalysisImmunofluorescence MicroscopyE8 Medium Culture

Related Articles